Public Accountability Unit
Tel: 020 8327 6920
133-155 Waterloo Road
London SE1 8UG
Our ref: 20/03/fb/1355
23 April 2019
Re: Internal Review Linked to case ref 1311 – Vaccine safety
Thank you for your email dated 20 March 2019 addressed to Public Health England (PHE).
Your request has been handled as an internal review.
Your request: I am writing to request an internal review of Public Health England's handling of my FOI
request 'Vaccine safety - aluminium adjuvant, trials'.
My question of evidence : independent scientific studies clearing aluminium adjuvants in
vaccines to be non-harmful to humans was not answered. I did not request findings on any
studies refuting any connection with autism, diabetes or asthma within vaccines.
We provided additional information which we thought you may have found of interest. With
regards to your initial request, within the link to Oxford Vaccine Group (that we sent in our
initial response) are further links to scientific studies that you requested. https://www.ncbi.nlm.nih.gov/pubmed/15152306 https://www.ncbi.nlm.nih.gov/pubmed/22001122.1 https://www.ncbi.nlm.nih.gov/pubmed/12184359.1 https://www.ncbi.nlm.nih.gov/pubmed/28919482
As stated in our previous response, the Oxford Vaccine Group provides independent
information about vaccines and infectious diseases. The site is regularly updated to ensure it
is as accurate as possible and meets the World Health Organisation’s criteria for providing
information regarding the safety of vaccines: http://vk.ovg.ox.ac.uk/vaccine-ingredients
PHE does not hold information on ‘independent scientific studies clearing aluminium
adjuvants to be non-harmful to humans injected within vaccines’. Reports of studies that
have specifically evaluated an Aluminium adjuvanted vaccine versus a non-adjuvanted
vaccine are publicly available.
The following papers report on Aluminium adjuvanted diphtheria/tetanus vaccine versus a
non-adjuvanted vaccine (plain whole cell diphtheria/tetanus/pertussis (DTP):
Waight PA, Pollock TM, Miller E, Coleman EM. Pyrexia after diphtheria/tetanus/pertussis
and diphtheria/tetanus vaccines. Archives of Disease in Childhood 1983, 58: 921-923. https://adc.bmj.com/content/archdischild/58/11/921.full.pdf
Pollock TM, Miller E, Mortimer JY, Smith G. Symptoms after primary immunisation with DTP
and with DT vaccine. Lancet 1984, i
: 146-149. https://www.ncbi.nlm.nih.gov/pubmed/6146044
The Medicines and Healthcare Products Regulatory Agency (MHRA) is the government
agency responsible for ensuring that vaccines used in the UK meet applicable standards of
safety, quality and efficacy. This agency has statutory responsibility for the safety of
vaccines in the UK.
Please note that you have the right to an independent review by the Information
Commissioner’s Office if a complaint cannot be resolved through the PHE complaints
procedure. The Information Commissioner’s Office can be contacted by writing to
Information Commissioner’s Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9